Researchers from the Icahn School of Medicine at Mount Sinai say they have developed a RNA and DNA sequencing platform that benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them.
The team described its methodology (“Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach”) in JCO Precision Oncology.
“Multiple myeloma (MM) is a malignancy of plasma cells, with a median survival of six years. Despite recent therapeutic advancements, relapse remains mostly inevitable, and the disease is fatal in the majority of patients. A major challenge in the treatment of patients with relapsed MM is the timely identification of treatment options in a personalized manner. Current approaches in precision oncology aim at matching specific DNA mutations to drugs, but incorporation of genome-wide RNA profiles has not yet been clinically assessed,” write the investigators.
“We have developed a novel computational platform for precision medicine of relapsed and/or refractory MM on the basis of DNA and RNA sequencing. Our approach expands on the traditional DNA-based approaches by integrating somatic mutations and copy number alterations with RNA-based drug repurposing and pathway analysis. We tested our approach in a pilot precision medicine clinical trial with 64 patients with relapsed and/or refractory MM.
Read more here: https://www.genengnews.com/gen-news-highlights/dnarna-sequencing-offers-hope-to-drug-resistant-multiple-myeloma-patients/81256117